NDA 213433 · Sun Pharm
Winlevi
Clascoterone · Topical · Androgen Receptor Inhibitor
NovelLast checked: Nov 19, 2026Latest source record: Mar 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 26, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
7 Phase 3, 4 recruiting
FAERS reports
1,419
75 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 2, 2025.
WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )
Mechanism: Clascoterone is an androgen receptor inhibitor. The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- WINLEVI · CLASCOTERONE 1% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clascoterone" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)Pivotal-lookingCompleted
Cassiopea SpAIndustry
NCT05914805 · 762 participants · Start Aug 17, 2023 · Primary completion Jul 16, 2025
Drug: Clascoterone 5% solution; Vehicle solution · For: Alopecia, Androgenetic
Sites: Scottsdale, Arizona; Hollywood, Florida; Atlanta, Georgia · 27 sites in all
- A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)Pivotal-lookingCompleted
Cassiopea SpAIndustry
NCT02608476 · 732 participants · Start Nov 16, 2015 · Primary completion Feb 21, 2018
Drug: CB-03-01 cream, 1%; Vehicle cream · For: Acne Vulgaris
Sites: Scottsdale, Arizona; Fort Smith, Arkansas; Sacramento, California · 52 sites in all
- A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)Pivotal-lookingCompleted
Cassiopea SpAIndustry
NCT02608450 · 708 participants · Start Jan 21, 2016 · Primary completion Apr 11, 2018
Drug: CB-03-01 cream, 1%; Vehicle cream · For: Acne Vulgaris
Sites: Little Rock, Arkansas; Fremont, California; Los Angeles, California · 54 sites in all
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair LossPivotal-lookingCompleted
Cassiopea SpAIndustry
NCT05910450 · 703 participants · Start Jun 21, 2023 · Primary completion Jan 26, 2026
Drug: Clascoterone 5% solution; Vehicle solution · For: Alopecia, Androgenetic
Sites: North Little Rock, Arkansas; San Diego, California; Jacksonville, Florida · 24 sites in all
- 1% Clascoterone Cream for the Treatment Acne VulgarisPivotal-lookingNot yet recruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT07457294 · 692 participants (planned) · Start May 4, 2026 · Primary completion Aug 7, 2028
Drug: 1% Clascoterone Cream; Placebo · For: Acne Vulgaris
- Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisPivotal-lookingRecruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT06403501 · 692 participants (planned) · Start May 20, 2024 · Primary completion Oct 2026
Drug: Clascoterone; Vehicle cream · For: Acne Vulgaris
Sites: Shanghai, China
- An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne VulgarisPivotal-lookingCompleted
Cassiopea SpAIndustry
NCT02682264 · 609 participants · Start Mar 9, 2016 · Primary completion Aug 31, 2018
Drug: CB-03-01 cream, 1% · For: Acne Vulgaris
Sites: Fort Smith, Arkansas; Little Rock, Arkansas; Sacramento, California · 74 sites in all
- A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne VulgarisPivotal-lookingCompleted
Intrepid Therapeutics, Inc.Industry
NCT01631474 · 363 participants · Start Jun 2012 · Primary completion Feb 2014
Drug: CB-03-01; Vehicle and 1 more · For: Acne Vulgaris
Sites: Los Angeles, California; San Diego, California; Sanford, Florida · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product storage error333
- product physical consistency issue329
- product use complaint286
- product dose omission issue184
- product use issue153
- drug ineffective146
- therapy cessation86
- poor quality product administered84
- product physical issue78
- condition aggravated76
- product quality issue67
- acne46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 500 |
| 2023 | 210 |
| 2024 | 422 |
| 2025 | 269 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Winlevi (Clascoterone)
2024 spending
$1.1M
Beneficiaries
809
1,883 claims
Per beneficiary
$1,385
$9.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $21,338 |
| 2022 | $514,981 |
| 2023 | $880,218 |
| 2024 | $1,120,073 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Topical Clascoterone for Acne Vulgaris.
Burma NE, Woo TE, Parsons L · Skin Therapy Lett 2022 · Clinical Trial, Phase III
- Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A, Thiboutot D, Stein Gold L, et al. · JAMA Dermatol 2020 · Clinical Trial, Phase III, Multicenter Study
- The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis.
Basendwh MA, Alharbi AA, Bukhamsin SA, et al. · PLoS One 2024 · Systematic Review, Comparative Study
- Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris.
Eichenfield LF, Gold LS, Han J, et al. · J Drugs Dermatol 2024 · Randomized Controlled Trial
- Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early-Phase Clinical Study Participants.
Di Stefano AFD, Radicioni MM, Garhöfer G, et al. · Clin Pharmacol Drug Dev 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Sun Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.